Science

Science

Response rates to immunotherapy remain unsatisfactorily low. Current approaches deliver these therapies systemically to patients with advanced disease. Concentrating immunotherapy where it is needed and when it is needed is preferable ‚Äď particularly in the context of miniscule tumor burden. Like a vaccine, local administration can generate systemic immunity, leading to eradication of residual disease throughout the body. SURGE‚Äôs approach, which reprograms the body‚Äôs response to surgery from immunosuppressive to immunostimulatory, should become an essential part of a patient‚Äôs course of treatment.

Post-surgical cancer recurrence & metastasis are devastating

Relapse & metastasis account for 90% of cancer-related deaths

Predina, J. et al., Proc Natl Acad Sci USA., 110(5):E415-424, 2013
Horowitz, M. et al., Nat Rev Clin Oncol., 12(4):213-226, 2015
Krall, J.A. et al., Sci Transl Med., 10(436):eaan3464, 2018

0%

Percentage of 700,000 annual domestic patients who recur post-surgery

0%

Percentage of other companies focusing surgery-induced immune suppression

Treatment landscape

A need for Intraoperative Immunotherapy

Pre-Surgery

SURGERY

Post-Surgery

METASTATIC

Publications

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases

Cancer immunotherapy can confer durable benefit, but the percentage of patients who respond to this approach remains modest. The ability to concentrate immunostimulatory compounds at the site of disease can overcome local immune tolerance and reduce systemic toxicity.

Improving cancer immunotherapy through nanotechnology

The 2018 Nobel Prize in Physiology or Medicine was awarded to pioneers in the field of cancer immunotherapy, as the utility of leveraging a patient’s coordinated and adaptive immune system to fight the patient’s unique tumour has now been validated robustly in the clinic. Still, the proportion of patients who respond to immunotherapy remains modest (~15% objective response rate across indications), as tumours have multiple means of immune evasion.

SURGE’s immunotherapy hydrogel is an investigational drug and has not yet been approved for commercial use by the US FDA.